SK&F107647: A Synthetic Hematoregulatory Peptide in Patients With Solid Tumor Malignancies
| Autor: | J, Nemunaitis, D E, Martin, D L, Willis, M I, Freed, B, Levitt, D A, Richards, J V, Cox, G T, Kimmel, W J, Hyman, D K, Jorkasky, D R, Brocks |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Peptide Gastroenterology Adjuvants Immunologic Pharmacokinetics Neoplasms Internal medicine Blood plasma Humans Medicine Aged chemistry.chemical_classification Volume of distribution Chemotherapy business.industry Middle Aged Hematopoiesis Endocrinology Oncology chemistry Toxicity Vomiting Female medicine.symptom business Oligopeptides |
| Zdroj: | American Journal of Clinical Oncology. 21:189-194 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199804000-00020 |
| Popis: | SKF107647 is a synthetic hematoregulatory peptide (HP) increases both the number and function of progenitor cells, enabling improved survival after lethal myelosuppression, lethal fungal infection, and lethal herpes simplex virus infection in murine models. This Phase I single-blind placebo-controlled dose-rising crossover trial examined the efficacy of SKF107647 in patients who had incurable solid tumor malignancies. Sixteen patients were treated. Six adverse events in 3 patients were considered to be possibly related to SKF107647; all were mild to moderate in nature (mild nervousness and agitation at 0.01 ng/kg, moderate fever and mild nausea at 0.1 ng/kg, elevated hepatic enzymes at 0.1 ng/kg, and mild vomiting at 1.0 ng/kg). Plasma half-life was 2.44 hours (+/-1.07 standard deviation). The observed area volume of distribution was 16.7 L (+/-7.7 standard deviation) and clearance was 5.04 L/hour (+/-1.83 standard deviation). When administered as a single 2-hour intravenous infusion at doses ranging from 0.01 to 100 ng/kg, SKF107647 is safe and well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|